Faro Viga (Sildenafil Citrate) is applied across domains where additional symptomatic support is needed in adults who experience specific circulatory challenges. This medication is commonly used to help manage symptomatic patterns related to Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH), and is considered relevant for severe peripheral circulatory compromise.

The medication provides supportive assistance, helping to ease the overall burden of symptoms that interfere with functional stability. For the primary indication, it offers symptomatic relief that contributes to maintaining functional stability for sexual activity, even in conditions associated with diabetes mellitus or post-surgical states. It is also relevant in clinical settings involving vasospasm and circulatory insufficiency, providing relief when symptoms create noticeable physiological strain.

“The primary goal is providing supportive assistance that helps patients cope more steadily with difficult episodes and symptoms that create noticeable functional strain.”

Quick Fact: Relief for Circulatory Functional Strain Faro Viga supports patients during difficult episodes by easing distress and assists with maintaining functional stability in key vascular-dependent areas of health.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Dapagliflozin

This information is based strictly on authoritative government regulatory documents and official labeling, defining who is eligible for use and who must be excluded.

Populations for Whom Use is Contraindicated

• Patients with a history of a serious hypersensitivity reaction to dapagliflozin or any component of its formulation (e.g., anaphylaxis or angioedema).
• Patients who are on dialysis.
• Patients with severe renal impairment (e.g., eGFR less than 30 mL/min/1.73 m^2) when the medicine is used primarily for glycemic control in certain Type 2 Diabetes Mellitus populations.

Populations with Restricted or Not Recommended Use

Eligibility-Related Restrictions

Prior to starting treatment, regulatory labeling specifies that the patient's volume status and renal function must be assessed, especially in patients who are elderly, have existing renal impairment, or are taking diuretics. The drug is also not recommended for the treatment of Chronic Kidney Disease in patients with polycystic kidney disease or those requiring recent immunosuppressive therapy for kidney disease.

The official interaction profile for Faro Viga is classified into specific domains covering metabolic conflict, circulatory reinforcement, and clearance modifiers, as documented in government regulatory sources. These classifications govern all formal restrictions.

Contraindicated Combinations

Co-administration with organic nitrates or nitric oxide donors is formally and strictly prohibited. This restriction is based on the documented pharmacodynamic conflict, which carries a high risk of severe, additive hypotensive effects. Regulatory labeling also restricts use alongside other PDE5 inhibitors.

Metabolic and Exposure Alterations

Faro Viga is predominantly cleared via the hepatic enzyme CYP3A4. Co-administration with strong inhibitors of this enzyme, such as Ritonavir or Ketoconazole, formally reduces the substance's clearance, resulting in a documented increase in its systemic exposure (AUC). Due to this pharmacokinetic effect, specific timing constraints are formally established for certain combinations in the regulatory documents. This increased exposure is also officially noted in patients with severe hepatic or renal impairment due to impaired drug clearance.

Other Documented Interactions

The use of Faro Viga with alpha-blockers or other antihypertensive agents is officially associated with an additive pharmacodynamic effect on blood pressure. Furthermore, consumption with a high-fat meal is documented to delay the rate of absorption and the time required to reach the maximum plasma concentration.

Faro Viga (Sildenafil Citrate) operates through a highly selective molecular mechanism, acting as a targeted inhibitor within the body’s natural signaling pathways that govern blood vessel function. The effect is strictly localized and dependent on the system being activated.

Selective Inhibition of the PDE5 Enzyme

The drug's mechanism is the selective competitive inhibition of the Phosphodiesterase Type 5 (PDE5) enzyme. This critical enzyme is naturally tasked with terminating the signal for smooth muscle relaxation by breaking down cyclic Guanosine Monophosphate (cGMP). By blocking PDE5, Faro Viga prevents this breakdown, resulting in the conservation and accumulation of cGMP.

Amplification of the NO-cGMP Pathway and Vasodilation

The rise in cGMP concentration directly amplifies the body's natural Nitric Oxide (NO)-cGMP signaling pathway. Increased cGMP activates downstream cellular processes that cause a rapid decrease in calcium concentration within smooth muscle cells. This cascade results in smooth muscle cell relaxation and localized vasodilation (widening of the blood vessels), leading to increased localized blood flow and tissue perfusion. The mechanism enhances a pre-existing signal but does not initiate it.

Mechanistic Dependency

The pharmacological action is physiologically constrained by the need for the upstream release of Nitric Oxide (NO) to begin the cGMP cascade. Without this initial signal, the enzyme PDE5 has no substrate, and the drug is functionally inert. This constraint ensures the resulting physiological effects are highly localized and occur only when the physiological signal for them has been initiated.

Faro Viga (Sildenafil Citrate) usage is governed by distinct protocols based on its approved indication, with specific instructions regarding administration route, dosage, and frequency.

For Erectile Dysfunction (ED), the medicine is taken orally on an as-needed, episodic basis. Administration is typically recommended approximately 1 hour prior to sexual activity, though the permitted window spans from 30 minutes to 4 hours before the event. The usual starting dose is 50 mg, which may be adjusted by a healthcare provider within the 25 mg to 100 mg range. The maximum recommended frequency is strictly once per day.

For Pulmonary Arterial Hypertension (PAH), the administration protocol is continuous. The standard 20 mg oral dose is taken three times a day (TID), with doses required to be spaced 4 to 6 hours apart. When oral intake is temporarily interrupted, the medicine may be given intravenously as a 10 mg bolus, also TID.

Oral forms can be taken with or without food, although a high-fat meal is noted to delay the drug's onset of action for the ED indication. The oral suspension requires reconstitution and must be shaken vigorously for 10 seconds before each administration. Dose modifications are mandated for certain populations: a reduced 25 mg starting dose is considered for older adults (65 years) and for patients with severe renal or hepatic impairment. This initial reduction is also required when the medicine is used concurrently with certain strong CYP3A4 inhibitors, where the maximum dose is restricted to 25 mg over a 48-hour period.

Research Evidence / Overview of studies for Faro Viga

This section provides an overview of the key clinical research conducted for Faro Viga (Sildenafil Citrate), based solely on authoritative governmental and peer-reviewed scientific sources. The text summarizes the types of studies that have explored the medicine, the measured outcomes, and the limitations or uncertainties that remain in the research landscape.

Evidence for use in Erectile Dysfunction (ED)

The evidence base for this medicine was built from short-term (e.g., 12-week) randomized, double-blind, placebo-controlled trials (RCTs). These studies monitored adult men who experienced conditions marked by functional limitations related to erectile function. Researchers examined patient-reported outcomes using standardized questionnaires, such as the International Index of Erectile Function (IIEF).

Studies exploring short-term symptom changes reported that the treated groups data show patterns related to changes in measured scores for the ability to achieve and maintain an erection during the study period compared to the placebo groups. The data exploring the durability of these patterns over multiple years primarily comes from open-label extension studies where patient assignment to the active medicine or placebo was not randomized, meaning the certainty remains low regarding long-term maintenance patterns.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research for PAH was also evaluated in short-term (e.g., 12 to 16-week) randomized, placebo-controlled trials in adult populations. These studies monitored patients for changes in exercise capacity, most commonly measured using the 6-minute walk distance (6MWD), and the time to a clinical worsening event.

Studies conducted during periods of increased symptom activity reported that the observed populations showed patterns related to measurements indicating a longer time before experiencing a clinical worsening event compared to those receiving placebo. Research found a difference in the measured 6MWD from baseline in the treated groups compared to the placebo groups over the initial study duration.

Research Gaps and Uncertainty: A key limitation is that research has not definitively established a clear effect on all-cause mortality in adult PAH patients. Furthermore, studies observing responses over defined time intervals have described a pattern where higher doses were associated with an increased number of events in the long-term extension phase for the pediatric population (children aged 1 to 17 years), highlighting the need for continued study in this specific subgroup.

Common questions about Faro Viga (FAQ)

Q: What is the approved use of Faro Viga?

A: Faro Viga is approved for the treatment of erectile dysfunction (ED) in adult males and for the treatment of pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of the lungs.

Q: How does Faro Viga work in the body?

A: Faro Viga belongs to a class of medications called phosphodiesterase type 5 (PDE5) inhibitors. When used for ED, the medication supports increased blood flow to the penis following sexual stimulation. When used for PAH, it assists by relaxing and widening the blood vessels in the lungs.

Q: What common side effects were observed in clinical trials?

A: Common adverse events reported in clinical trials for ED have included headache, flushing, upset stomach, abnormal vision (such as a bluish tint), and nasal congestion. For PAH, common adverse events may also include nosebleeds and difficulty sleeping. Not all individuals experience side effects.

Q: Is Faro Viga safe for everyone?

A: The use of Faro Viga is contraindicated in individuals who take nitrates (often prescribed for chest pain) due to a risk of severely low blood pressure. Individuals should not take this medication if they have a known allergy to sildenafil. A healthcare provider must evaluate a patient's medical history before prescribing it.

Q: What are the possible serious side effects?

A: Rarely, serious adverse events have been reported, including priapism (an erection lasting longer than four hours, which requires immediate medical attention), sudden decrease or loss of vision, and sudden decrease or loss of hearing. These events are uncommon but necessitate prompt consultation with a healthcare professional.

The official requirements for storing and disposing of Faro Viga are specified on the product label to maintain its stability and ensure safe handling.

Storage Requirements

The medication must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from both light and excessive moisture, and it must be kept in the original, tightly closed container at all times. The label explicitly states the medication must not be refrigerated or frozen. If the product is in an oral dosage form, a stability restriction may apply, such as a 60-day discard period after the original container is opened.

Disposal Requirements

To prevent accidental exposure or environmental contamination, Faro Viga should not be poured down a drain or thrown into household trash. Disposal should be carried out through an authorized drug take-back program (e.g., pharmacy kiosk or DEA collection event). Additionally, the label mandates that the product be stored out of the sight and reach of children.